ClinicalTrials.gg
CompletedNCT02066389Updated Jul 30, 2021Results posted

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

A Phase 2 interventional study of Placebo and Upadacitinib in Rheumatoid Arthritis, sponsored by AbbVie. Completed at 63 sites in 16 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-07-30.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.

Enrollment
10th of 19
300 · median 300
Started
2014
with 1 other
Phase 2
7 of 19
2 open now
Registered
4th of 19
by date
Lead sponsor
13 of 19
AbbVie

Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 10th largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 2, and was the 4th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing upadacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective of the study was to compare the safety and efficacy of multiple doses of upadacitinib versus placebo in adults with moderately to severely active rheumatoid arthritis (RA) on stable background methotrexate therapy who had not shown an adequate response to methotrexate alone.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Musculoskeletal Disease
  • Arthritis
  • Joint Diseases
  • anti-inflammatory agents
  • antirheumatic agents
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with RA based on either the 1987-revised American College of Rheumatology (ACR) classification criteria or the 2010 ACR/European League against Rheumatism (EULAR) criteria for ≥ 3 months.
  2. Have active RA as defined by the following minimum disease activity criteria:

    • ≥ 6 swollen joints (based on 66 joint counts) at Screening and Baseline Visits.
    • ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.
    • high-sensitivity C-reactive protein (hsCRP) > (ULN) OR positive for both rheumatoid factor and anti-cyclic citrullinated peptide (CCP) at Screening.
  3. Subjects must have been receiving oral or parenteral methotrexate therapy ≥ 3 months and on a stable prescription of 7.5 to 25 mg/week for at least 4 weeks prior to Baseline Visit. Subjects should also be on a stable dose of folic acid (or equivalent) for at least 4 weeks prior to Baseline Visit. Subjects should continue with their stable doses of methotrexate and folic acid throughout the study.
  4. Except for MTX, subjects must have discontinued all oral disease-modifying anti-rheumatic drugs (DMARDs) prior to Baseline Visit as specified below or for at least five times the mean terminal elimination half-life of a drug, whichever is longer:

    • ≥ 4 weeks prior to Baseline Visit for minocycline, penicillamine, sulfasalazine, hydroxychloroquine, chloroquine, azathioprine, gold formulations, cyclophosphamide
    • ≥ 8 weeks prior to Baseline Visit for leflunomide if no elimination procedure was followed, or adhere to a procedure (i.e., 11 days washout with colestyramine, or 30 days washout with activated charcoal)
  5. Subject has a negative tuberculosis (TB) Screening Assessment. If the subject has evidence of a latent TB infection, the subject must initiate and complete a minimum of 2 weeks (or per local guidelines, whichever is longer) of an ongoing TB prophylaxis or have documented completion of a full course of TB prophylaxis, prior to Baseline Visit.
  6. Subjects can be taking non-steroidal anti-inflammatory drugs (NSAIDS), acetaminophen, oral (equivalent to prednisone ≤ 10 mg), or inhaled corticosteroids at a stable dose for at least 4 weeks prior to Baseline Visit for stable medical conditions and should be kept at a stable dose throughout the study. NSAIDs, acetaminophen, tramadol, codeine, hydrocodone and propoxyphene taken as needed are allowed but may not be taken 24 hours prior to any study visit. Oral and inhaled corticosteroids taken as needed are allowed but may not be taken 24 hours prior to any study visit.
  7. Subjects must have discontinued high potency opiates including (but not limited to): oxycodone, oxymorphone, fentanyl, levorphanol, buprenorphine, methadone, hydromorphone, and morphine at least 4 weeks prior to Baseline Visit.

Exclusion criteria

Exclusion Criteria:

  1. Female who is pregnant or breastfeeding.
  2. Prior exposure to Janus activated kinase (JAK) inhibitor (e.g., tofacitinib, baricitinib).
  3. Prior exposure to any or approved biologic RA therapy.
  4. Receipt of any investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives of the drug (whichever is longer) prior to Week 0 Visit.
  5. Current or expected need of other medications, except methotrexate. Use of oral intake of > 10 mg prednisone/day or equivalent therapy (see inclusion criterion 7).
  6. Subject has been treated with intra-articular or parenteral administration of corticosteroids in the preceding 8 weeks prior to the Week 0 Visit.
  7. Screening laboratory values meeting the following criteria:

    • Serum (AST) or alanine transaminase (ALT) > 1.5 ×
    • Estimated (eGRF) by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula \< 40 mL/min/1.73 m²
    • Total white blood cell count (WBC) \< 3,000/µL
    • (ANC) \< 1,200/µL
    • count \< 100,000/µL
    • Absolute lymphocytes count \< 750/ µL
    • \< 9 gm/dL
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo capsules twice daily for 12 weeks.

    Drug: Placebo

  • Experimental
    Upadacitinib 3 mg BID

    Participants received 3 mg upadacitinib twice daily (BID) for 12 weeks.

    Drug: Upadacitinib

  • Experimental
    Upadacitinib 6 mg BID

    Participants received 6 mg upadacitinib twice daily (BID) for 12 weeks.

    Drug: Upadacitinib

  • Experimental
    Upadacitinib 12 mg BID

    Participants received 12 mg upadacitinib twice daily (BID) for 12 weeks.

    Drug: Upadacitinib

  • Experimental
    Upadacitinib 18 mg BID

    Participants received 18 mg upadacitinib twice daily (BID) for 12 weeks.

    Drug: Upadacitinib

  • Experimental
    Upadacitinib 24 mg QD

    Participants received 24 mg upadacitinib once daily (QD) for 12 weeks.

    Drug: Upadacitinib

Interventions

  • DrugPlacebo

    Tablets for oral administration

  • Tablets for oral administration

    Also known as: ABT-494

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

    A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 50% improvement in 68-tender joint count; * ≥ 50% improvement in 66-swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician's global assessment of disease activity * Patient's global assessment of disease activity * Patient's assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  2. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12

    A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  3. Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12

    The disease activity score-28-CRP (DAS28 \[CRP\]) assesses RA disease activity based on a continuous scale of combined measures of 28 tender joint counts (TJC28), 28 swollen joint counts (SJC28), C-reactive protein (CRP), and the patient global assessment of disease activity (measured on a visual analog scale (VAS) from 0 to 100 mm). DAS28(CRP) scores range from 0 to approximately 10 where higher scores indicate more disease activity. LDA is defined as a DAS28(CRP) score \< 3.2.

    Time frame: Week 12

  4. Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12

    The disease activity score-28-CRP (DAS28 \[CRP\]) assesses RA disease activity based on a continuous scale of combined measures of 28 tender joint counts (TJC28), 28 swollen joint counts (SJC28), C-reactive protein (CRP), and the patient global assessment of disease activity (measured on a visual analog scale from 0 to 100 mm). DAS28(CRP) scores range from 0 to 10 where higher scores indicate more disease activity. CR is defined as a DAS28(CRP) score \< 2.6.

    Time frame: Week 12

  5. Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12

    The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA is defined as a CDAI score ≤ 10.

    Time frame: Week 12

  6. Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 12

    The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. CR is defined as a CDAI score ≤ 2.8.

    Time frame: Week 12

07

Results

Posted Oct 4, 2019

Participant flow

A total of 300 adults with rheumatoid arthritis (RA) were enrolled at 59 study sites located in 16 countries.

Participant flow — Overall Study
MilestonePlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QD
Started505050505050
Received study drug505050505049
Completed454944474345
Not completed516375
Withdrew: Adverse event111151
Withdrew: Withdrawal by subject405112
Withdrew: Lost to follow-up000111
Withdrew: Randomized in error000001

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
percentage of participantsPlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QD
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1250.064.673.581.676.681.6
Statistical analysis
  • Placebo vs Upadacitinib 3 mg BID · Chi-squared · p = 0.153 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 6 mg BID · Chi-squared · p = 0.018 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 12 mg BID · Chi-squared · p = 0.001 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 18 mg BID · Chi-squared · p = 0.008 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 24 mg QD · Chi-squared · p = 0.001 (Statistical tests were 1-sided at a significance level of 0.05.)
SecondaryPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 50% improvement in 68-tender joint count; * ≥ 50% improvement in 66-swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician's global assessment of disease activity * Patient's global assessment of disease activity * Patient's assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
percentage of participantsPlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QD
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 1219.639.649.050.044.743.8
Statistical analysis
  • Placebo vs Upadacitinib 3 mg BID · Chi-squared · p = 0.034 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 6 mg BID · Chi-squared · p = 0.003 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 12 mg BID · Chi-squared · p = 0.002 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 18 mg BID · Chi-squared · p = 0.010 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 24 mg QD · Chi-squared · p = 0.012 (Statistical tests were 1-sided at a significance level of 0.05.)
SecondaryPercentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12

A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
percentage of participantsPlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QD
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 126.523.430.616.027.725.0
Statistical analysis
  • Placebo vs Upadacitinib 3 mg BID · Chi-squared · p = 0.023 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 6 mg BID · Chi-squared · p = 0.003 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 12 mg BID · Chi-squared · p = 0.145 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 18 mg BID · Chi-squared · p = 0.007 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 24 mg QD · Chi-squared · p = 0.014 (Statistical tests were 1-sided at a significance level of 0.05.)
SecondaryPercentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12

The disease activity score-28-CRP (DAS28 \[CRP\]) assesses RA disease activity based on a continuous scale of combined measures of 28 tender joint counts (TJC28), 28 swollen joint counts (SJC28), C-reactive protein (CRP), and the patient global assessment of disease activity (measured on a visual analog scale (VAS) from 0 to 100 mm). DAS28(CRP) scores range from 0 to approximately 10 where higher scores indicate more disease activity. LDA is defined as a DAS28(CRP) score \< 3.2.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
percentage of participantsPlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QD
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 1221.349.057.146.051.042.9
Statistical analysis
  • Placebo vs Upadacitinib 3 mg BID · Fisher Exact · p = 0.005 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 6 mg BID · Fisher Exact · p = <0.001 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 12 mg BID · Fisher Exact · p = 0.010 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 18 mg BID · Fisher Exact · p = 0.002 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 24 mg QD · Fisher Exact · p = 0.024 (Statistical tests were 1-sided at a significance level of 0.05.)
SecondarySecondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12

The disease activity score-28-CRP (DAS28 \[CRP\]) assesses RA disease activity based on a continuous scale of combined measures of 28 tender joint counts (TJC28), 28 swollen joint counts (SJC28), C-reactive protein (CRP), and the patient global assessment of disease activity (measured on a visual analog scale from 0 to 100 mm). DAS28(CRP) scores range from 0 to 10 where higher scores indicate more disease activity. CR is defined as a DAS28(CRP) score \< 2.6.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12
percentage of participantsPlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QD
Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 1214.936.738.834.042.922.4
Statistical analysis
  • Placebo vs Upadacitinib 3 mg BID · Chi-squared · p = 0.015 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 6 mg BID · Chi-squared · p = 0.008 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 12 mg BID · Chi-squared · p = 0.029 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 18 mg BID · Chi-squared · p = 0.003 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 24 mg QD · Chi-squared · p = 0.343 (Statistical tests were 1-sided at a significance level of 0.05.)
SecondaryPercentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12

The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA is defined as a CDAI score ≤ 10.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12
percentage of participantsPlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QD
Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 1221.340.840.840.049.036.7
Statistical analysis
  • Placebo vs Upadacitinib 3 mg BID · Chi-squared · p = 0.039 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 6 mg BID · Chi-squared · p = 0.039 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 12 mg BID · Chi-squared · p = 0.046 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 18 mg BID · Chi-squared · p = 0.005 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 24 mg QD · Chi-squared · p = 0.096 (Statistical tests were 1-sided at a significance level of 0.05.)
SecondaryPercentage of Participants Achieving Clinical Remission Based on CDAI at Week 12

The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. CR is defined as a CDAI score ≤ 2.8.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 12
percentage of participantsPlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QD
Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 124.312.214.36.014.36.1
Statistical analysis
  • Placebo vs Upadacitinib 3 mg BID · Chi-squared · p = 0.269 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 6 mg BID · Chi-squared · p = 0.160 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 12 mg BID · Chi-squared · p = 1.000 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 18 mg BID · Chi-squared · p = 0.160 (Statistical tests were 1-sided at a significance level of 0.05.)
  • Placebo vs Upadacitinib 24 mg QD · Chi-squared · p = 1.000 (Statistical tests were 1-sided at a significance level of 0.05.)

Adverse events

Collected over From the first dose of study drug until 30 days after last dose (up to 16 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/50 (0%)0/50 (0%)2/50 (4%)
Upadacitinib 3 mg BID0/50 (0%)0/50 (0%)5/50 (10%)
Upadacitinib 6 mg BID0/50 (0%)2/50 (4%)7/50 (14%)
Upadacitinib 12 mg BID0/50 (0%)1/50 (2%)17/50 (34%)
Upadacitinib 18 mg BID0/50 (0%)3/50 (6%)6/50 (12%)
Upadacitinib 24 mg QD0/49 (0%)2/49 (4.1%)6/49 (12.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QD
FOREARM FRACTUREInjury, poisoning and procedural complications0/500/500/500/500/501/49
HEAD INJURYInjury, poisoning and procedural complications0/500/500/500/500/501/49
SYNCOPENervous system disorders0/500/500/500/500/501/49
PYREXIAGeneral disorders0/500/500/500/501/500/49
PNEUMONIAInfections and infestations0/500/500/501/500/500/49
OSTEONECROSISMusculoskeletal and connective tissue disorders0/500/501/500/500/500/49
LUNG NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/500/501/500/500/500/49
SCIATICANervous system disorders0/500/500/500/501/500/49
OVARIAN CYSTReproductive system and breast disorders0/500/500/500/501/500/49
Most frequent other events
Most frequent other events
EventPlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QD
INFLUENZAInfections and infestations0/500/500/504/501/500/49
NASOPHARYNGITISInfections and infestations1/501/502/504/502/503/49
LEUKOPENIABlood and lymphatic system disorders0/500/500/503/501/500/49
DIARRHOEAGastrointestinal disorders0/500/501/503/501/501/49
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations0/500/500/503/502/501/49
DYSLIPIDAEMIAMetabolism and nutrition disorders0/501/500/503/500/500/49
BACK PAINMusculoskeletal and connective tissue disorders0/501/503/501/500/501/49
HEADACHENervous system disorders1/502/501/503/500/501/49
COUGHRespiratory, thoracic and mediastinal disorders0/501/501/503/501/500/49

Baseline characteristics

All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QDTotal
Mean54.5 ± 11.5153.1 ± 12.1554.8 ± 12.4755.7 ± 11.6554.6 ± 13.6556.2 ± 11.7954.8 ± 12.16
Age, Customized
Age, Customized(Participants)PlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QDTotal
18 to < 45 years9119713756
45 to < 65 years323030322527176
≤ 65 years991111121567
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QDTotal
Female384034414242237
Male12101698762
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QDTotal
Hispanic or Latino11817177868
Not Hispanic or Latino394233334341231
Unknown or Not Reported0000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboUpadacitinib 3 mg BIDUpadacitinib 6 mg BIDUpadacitinib 12 mg BIDUpadacitinib 18 mg BIDUpadacitinib 24 mg QDTotal
White504849484949293
Black or African American0111003
Multi-race0101103
08

Study locations

63 sites
  • C.V. Mehta MD, Med Corporation /ID# 126380
    Hemet, California 92543, United States
  • Omega Research Consultants, LLC /ID# 125780
    DeBary, Florida 32713-2260, United States
  • Lovelace Scientific Resources /ID# 127324
    Venice, Florida 34292, United States
  • North Georgia Rheumatology Grp /ID# 125779
    Lawrenceville, Georgia 30045, United States
  • PRN Professional Research Network of Kansas, LLC /ID# 126148
    Wichita, Kansas 67205, United States
  • The Center for Rheumatology & /ID# 127323
    Wheaton, Maryland 20902, United States
  • Summit Medical Group /ID# 125776
    Clifton, New Jersey 07012, United States
  • Arthritis and Osteo Assoc /ID# 134994
    Las Cruces, New Mexico 88011, United States
  • Altoona Ctr Clinical Res /ID# 125777
    Duncansville, Pennsylvania 16635, United States
  • Emkey Arthritis and Osteo Clin /ID# 134716
    Wyomissing, Pennsylvania 19610, United States
  • Accurate Clinical Research /ID# 126535
    Houston, Texas 77034, United States
  • Mountain State Clinical Resear /ID# 127089
    Clarksburg, West Virginia 26301, United States
  • MHAT Trimontsium /ID# 127311
    Plovdiv, 4000, Bulgaria
  • UMHAT Pulmed OOD /ID# 127307
    Plovdiv, 4000, Bulgaria
  • MHAT Kaspela /ID# 127315
    Plovdiv, 4001, Bulgaria
  • Diagnostic Consultative Center /ID# 127313
    Sofia, 1612, Bulgaria
  • UMHAT Sv. Ivan Rilski /ID# 127314
    Sofia, 1612, Bulgaria
  • UMHAT Sv. Ivan Rilski /ID# 131608
    Sofia, 1612, Bulgaria
  • Diagnostic Consultative Center /ID# 127312
    Varna, 9000, Bulgaria
  • Corp de Beneficencia Osorno /ID# 127337
    Osorno, 1710216, Chile
  • Quantum Research LTDA. /ID# 127338
    Puerto Varas, 5550170, Chile
  • Revmatologicky ustav Praha /ID# 127317
    Prague 2, Praha 2 128 00, Czechia
  • Nuselská poliklinika, Revmatologie /ID# 127318
    Prague 4, Praha 4 140 00, Czechia
  • Revmatologie Bruntal, s.r.o /ID# 126881
    Bruntál, 79201, Czechia
  • Artroscan s.r.o. /ID# 126845
    Ostrava, 722 00, Czechia
  • Qualiclinic Kft. /ID# 127340
    Budapest III, Pest 1036, Hungary
  • Veszprem Megyei Csolnoky Feren /ID# 126876
    Veszprém, 8200, Hungary
  • Barzilai Medical Center /ID# 126875
    Ashkelon, 78278, Israel
  • Rambam Health Care Campus /ID# 127341
    Haifa, 3109601, Israel
  • Sheba Medical Center /ID# 126878
    Ramat Gan, 5262100, Israel
  • LTD M&M Centers /ID# 127346
    Adazi, 2164, Latvia
  • Arija's Ancane's Family Doctor /ID# 127342
    Baldone, 2125, Latvia
  • Clinic ORTO /ID# 127345
    Riga, 1005, Latvia
  • Hospital de Jesús Nazareno /ID# 127352
    Mexico City, 06090, Mexico
  • Cliditer SA de CV /ID# 127347
    Mexico City, 06700, Mexico
  • Clinstile, S.A. de C.V. /ID# 127350
    Mexico City, 06700, Mexico
  • REUMED Sp.z o.o. Filia nr 1 /ID# 127353
    Lublin, Lubelskie 20-607, Poland
  • Centrum Medyczne Pratia Krakow /ID# 127358
    Krakow, Malopolskie 30-002, Poland
  • NBR Polska /ID# 127359
    Warsaw, Mazowieckie 00-465, Poland
  • Medica Pro Familia S.A Warszawa /ID# 127361
    Warsaw, Mazowieckie 01-869, Poland
  • Gabinet Internistyczno Reum. /ID# 127357
    Białystok, Podlaskie 15-099, Poland
  • Centrum Medyczne Pratia Gdynia /ID# 127360
    Gdynia, Pomorskie 81-338, Poland
  • Michal Bazela Higher-Med /ID# 127355
    Elbląg, Warminsko-mazurskie 82-300, Poland
  • GCM Medical Group /ID# 127363
    San Juan, 00909, Puerto Rico
  • City Clinical Hospital #7 /ID# 127372
    Kazan, Tatarstan, Respublika 420103, Russian Federation
  • Tver Regional Clinical Hosp. /ID# 127375
    Tver, Tverskaya Oblast 170036, Russian Federation
  • II Dzhan Research Center /ID# 127376
    St. Petersburg, 192242, Russian Federation
  • MEDMAN s.r.o. /ID# 127381
    Martin, 036 01, Slovakia
  • Poliklinika Senica /ID# 127396
    Senica, 905 01, Slovakia
  • Panorama Medical Centre /ID# 126846
    Cape Town, Western Cape 7500, South Africa
  • Winelands Medical Research Ctr /ID# 126844
    Stellenbosch, Western Cape 7600, South Africa
  • Hospital Regional de Malaga /ID# 127385
    Málaga, Malaga 29009, Spain
  • Hospital Plató /ID# 127384
    Barcelona, 08006, Spain
  • Hospital CIMA Sanitas /ID# 127383
    Barcelona, 08034, Spain
  • Hospital Universitario Basurto /ID# 127391
    Bilbao, 48013, Spain
  • Hospital Clin Univ San Carlos /ID# 127382
    Madrid, 28040, Spain
  • Clinica Gaias /ID# 127386
    Santiago de Compostela, 15702, Spain
  • Hospital Infanta Luisa /ID# 127389
    Sevilla, 41010, Spain
  • Hospital Universitario de Valm /ID# 127387
    Sevilla, 41014, Spain
  • Medeniyet Univ. Goztepe Traini /ID# 132396
    Istanbul, 34000, Turkey
  • Kiev Municipal Clin Hosp 3 /ID# 127419
    Kiev, 02125, Ukraine
  • NSC-Strazhesko Ist Cardiology /ID# 127416
    Kiev, 03680, Ukraine
  • Sumy State University /ID# 127418
    Sumy, 40000, Ukraine
09

References and documents

Publications

  • Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2016 Dec;68(12):2857-2866. doi: 10.1002/art.39808. PubMed 27390150 ↗
  • Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27. PubMed 34041702 ↗
  • Nader A, Mohamed MF, Winzenborg I, Doelger E, Noertersheuser P, Pangan AL, Othman AA. Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis. Clin Pharmacol Ther. 2020 Apr;107(4):994-1003. doi: 10.1002/cpt.1671. Epub 2019 Nov 30. PubMed 31610021 ↗
  • Mohamed MF, Klunder B, Camp HS, Othman AA. Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection. Clin Pharmacol Ther. 2019 Dec;106(6):1319-1327. doi: 10.1002/cpt.1543. Epub 2019 Aug 23. PubMed 31194885 ↗
  • Klunder B, Mohamed MF, Othman AA. Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials. Clin Pharmacokinet. 2018 Aug;57(8):977-988. doi: 10.1007/s40262-017-0605-6. PubMed 29076110 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jul 2015, 15 months.

Results were first posted in Oct 2019, 4 years 3 months after primary completion. A results delay was requested in Jun 2016.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 15 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2014
First posted
Feb 19, 2014
StartActual
Mar 26, 2014
Primary completionActual
Jul 2, 2015
CompletionActual
Jul 2, 2015
Results delay requested
Jun 15, 2016
Results first posted
Oct 4, 2019
Last update
Jul 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02066389
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 19, 2014
Start date
Mar 26, 2014
Primary completion
Jul 2, 2015
Completion
Jul 2, 2015
Results posted
Oct 4, 2019
Last update
Jul 30, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion